{"id":"cyclophosphamide-azathioprine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Myelosuppression"},{"rate":"10-20%","effect":"Nausea and vomiting"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Infections"},{"rate":"5-10%","effect":"Hair loss"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Cyclophosphamide works by adding an alkyl group to the DNA of cancer cells, causing cross-linking and interfering with DNA replication. Azathioprine, on the other hand, is converted into 6-mercaptopurine, which inhibits the synthesis of purines, thereby suppressing the immune system. This dual mechanism of action makes cyclophosphamide/azathioprine effective in treating various types of cancer and autoimmune diseases.","oneSentence":"Cyclophosphamide is an alkylating agent that interferes with DNA replication, while azathioprine is a purine synthesis inhibitor that suppresses the immune system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:34.992Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of certain types of cancer, such as lymphomas and leukemias, and autoimmune diseases, such as rheumatoid arthritis and lupus"},{"name":"Prevention of organ rejection in transplant patients"}]},"trialDetails":[{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT02807103","phase":"PHASE3","title":"Rituximab in Eosinophilic Granulomatosis With Polyangiitis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-12-05","conditions":"Eosinophilic Granulomatosis With Polyangiitis (EGPA)","enrollment":107},{"nctId":"NCT04745728","phase":"PHASE3","title":"Different Immunosuppressive Treatment in iMN","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2021-04-14","conditions":"Idiopathic Membranous Nephropathy","enrollment":200},{"nctId":"NCT07168161","phase":"PHASE3","title":"BDB-001 Phase III Trial in ANCA-Associated Vasculitis","status":"RECRUITING","sponsor":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","startDate":"2025-11-10","conditions":"ANCA Associated Vasculitis (AAV)","enrollment":300},{"nctId":"NCT05030155","phase":"PHASE3","title":"Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-05-30","conditions":"Eosinophilic Granulomatosis With Polyangiitis","enrollment":100},{"nctId":"NCT04362293","phase":"PHASE2","title":"Reduced Intensity Transplantation for Severe Sickle Cell Disease","status":"SUSPENDED","sponsor":"St. Jude Children's Research Hospital","startDate":"2020-04-30","conditions":"Sickle Cell Disease","enrollment":40},{"nctId":"NCT01461837","phase":"PHASE2","title":"Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York Medical College","startDate":"2012-01","conditions":"Sickle Cell Disease","enrollment":21},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":"Connective Tissue Diseases, Thrombocytopenia","enrollment":296},{"nctId":"NCT02994927","phase":"PHASE3","title":"A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-15","conditions":"ANCA-Associated Vasculitis","enrollment":331},{"nctId":"NCT06226662","phase":"PHASE2","title":"Study of NM8074 in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (AAV)","status":"NOT_YET_RECRUITING","sponsor":"NovelMed Therapeutics","startDate":"2026-06","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":12},{"nctId":"NCT06846255","phase":"PHASE4","title":"Comparing DCP and DAP for Pemphigus Vulgaris","status":"COMPLETED","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2021-06-15","conditions":"Pemphigus Vulgaris","enrollment":66},{"nctId":"NCT02954939","phase":"NA","title":"The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2017-03-01","conditions":"Lupus Nephritis","enrollment":50},{"nctId":"NCT05149768","phase":"PHASE2","title":"Open Label Extension Study of Brentuximab Vedotin in Early dcSSc","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2024-02-14","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":11},{"nctId":"NCT00103792","phase":"PHASE3","title":"Mycophenolate Mofetil for Treatment of Relapses of Wegener's Disease or Microscopic Polyangiitis (MPA)","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2004-12","conditions":"Wegener's Granulomatosis, Vasculitis","enrollment":84},{"nctId":"NCT05247203","phase":"PHASE1","title":"Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2022-05-11","conditions":"Systemic Lupus Erythematosus","enrollment":92},{"nctId":"NCT03198689","phase":"PHASE2","title":"Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-05-07","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":11},{"nctId":"NCT03096275","phase":"PHASE3","title":"Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis","status":"COMPLETED","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2017-03-16","conditions":"Takayasu Arteritis","enrollment":138},{"nctId":"NCT04082416","phase":"PHASE3","title":"Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2019-10-16","conditions":"Systemic Lupus Erythematosus","enrollment":335},{"nctId":"NCT02444728","phase":"PHASE3","title":"Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE","status":"TERMINATED","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2015-07","conditions":"Thrombocytopenia","enrollment":50},{"nctId":"NCT05207358","phase":"PHASE4","title":"Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis","status":"RECRUITING","sponsor":"Institutul Clinic Fundeni","startDate":"2022-03-02","conditions":"Lupus Nephritis","enrollment":30},{"nctId":"NCT04101578","phase":"","title":"Clinical Prognosis and Progression of Myasthenia Gravis Patients","status":"UNKNOWN","sponsor":"Da, Yuwei, M.D.","startDate":"2017-02-08","conditions":"Myasthenia Gravis","enrollment":2000},{"nctId":"NCT01639339","phase":"PHASE3","title":"Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis","status":"COMPLETED","sponsor":"Human Genome Sciences Inc., a GSK Company","startDate":"2012-07-12","conditions":"Lupus Nephritis","enrollment":448},{"nctId":"NCT03770663","phase":"PHASE3","title":"Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-02-05","conditions":"Antisynthetase Syndrome (ASS), Interstitial Lung Disease","enrollment":76},{"nctId":"NCT02297126","phase":"NA","title":"A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program","status":"COMPLETED","sponsor":"Indiana University","startDate":"2015-03","conditions":"Adverse Drug Reaction","enrollment":4465},{"nctId":"NCT00626197","phase":"PHASE3","title":"A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)","status":"TERMINATED","sponsor":"Genentech, Inc.","startDate":"2008-02-15","conditions":"Lupus Nephritis, Systemic Lupus Erythematosus","enrollment":381},{"nctId":"NCT02885610","phase":"PHASE2","title":"Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)","status":"COMPLETED","sponsor":"RemeGen Co., Ltd.","startDate":"2015-12","conditions":"Systemic Lupus Erythematosus","enrollment":249},{"nctId":"NCT03791827","phase":"","title":"Multicenter Registry of Pediatric Lupus Nephritis in China","status":"UNKNOWN","sponsor":"Xiqiang Dang","startDate":"2018-12-01","conditions":"Lupus Nephritis, Children, Steroid","enrollment":1200},{"nctId":"NCT03886233","phase":"","title":"Treatment Outcome of Uveitis in Autoimmune Diseases","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-03","conditions":"Autoimmune Uveitis","enrollment":1},{"nctId":"NCT03468972","phase":"PHASE4","title":"Effect of Immunosuppression in IgA Nephropathy","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2019-03","conditions":"Biopsy-proven IgA Nephropathy","enrollment":174},{"nctId":"NCT02936375","phase":"PHASE2","title":"The Iguratimod Effect on Lupus Nephritis (IGeLU)","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2017-09-07","conditions":"Lupus Nephritis","enrollment":120},{"nctId":"NCT00336414","phase":"PHASE3","title":"Five-Year Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis","status":"WITHDRAWN","sponsor":"Istituto Giannina Gaslini","startDate":"2006-06","conditions":"Systemic Lupus Erythematosus Nephritis","enrollment":""},{"nctId":"NCT02294344","phase":"NA","title":"The Clinical Efficacy of DFPP in Patients With AAGN","status":"TERMINATED","sponsor":"Zhi-Hong Liu, M.D.","startDate":"2014-06","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":14},{"nctId":"NCT02728271","phase":"EARLY_PHASE1","title":"Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome","status":"TERMINATED","sponsor":"Mounzer Agha","startDate":"2016-04","conditions":"Churg-Strauss Syndrome","enrollment":1},{"nctId":"NCT00152113","phase":"PHASE1","title":"Haploidentical Stem Cell Transplant for Patients With Sickle Cell Disease and Prior Stroke or Abnormal Transcranial Ultrasound","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2005-04","conditions":"Sickle Cell Disease","enrollment":5},{"nctId":"NCT00104299","phase":"PHASE2, PHASE3","title":"Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-01","conditions":"Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis","enrollment":197},{"nctId":"NCT02645565","phase":"PHASE4","title":"Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis","status":"COMPLETED","sponsor":"Jawaharlal Institute of Postgraduate Medical Education & Research","startDate":"2015-12","conditions":"Lupus Nephritis","enrollment":75},{"nctId":"NCT01275287","phase":"PHASE2","title":"Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2011-05","conditions":"Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","enrollment":""},{"nctId":"NCT00132691","phase":"PHASE4","title":"Multicenter Uveitis Steroid Treatment (MUST) Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2005-09","conditions":"Uveitis","enrollment":255},{"nctId":"NCT00774852","phase":"PHASE2","title":"Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-11","conditions":"Lupus Nephritis, Lupus Erythematosus, Systemic","enrollment":137},{"nctId":"NCT01834157","phase":"","title":"Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis","status":"UNKNOWN","sponsor":"Prof. Laszlo Czirjak","startDate":"2013-04","conditions":"Systemic Sclerosis, Arthritis","enrollment":160},{"nctId":"NCT00554502","phase":"PHASE3","title":"Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy","status":"COMPLETED","sponsor":"RWTH Aachen University","startDate":"2008-02","conditions":"IgA Nephropathy","enrollment":148},{"nctId":"NCT01446211","phase":"PHASE3","title":"Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis","status":"TERMINATED","sponsor":"Nordic Pharma SAS","startDate":"2011-11","conditions":"Wegeners Granulomatosis","enrollment":4},{"nctId":"NCT00425438","phase":"PHASE3","title":"A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2007-03","conditions":"Lupus Nephritis","enrollment":52},{"nctId":"NCT01858259","phase":"","title":"Treatment and Prevention of Progression of Interstitial Lung Disease in Systemic Sclerosis","status":"UNKNOWN","sponsor":"Gabriela Riemekasten","startDate":"2013-05","conditions":"Systemic Sclerosis, Interstitial Lung Diseases","enrollment":1372},{"nctId":"NCT01646385","phase":"","title":"Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-02","conditions":"Rheumatoid Arthritis","enrollment":6393},{"nctId":"NCT02135380","phase":"PHASE1, PHASE2","title":"Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis","status":"UNKNOWN","sponsor":"Kasiak Research Pvt. Ltd.","startDate":"2014-08","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":60},{"nctId":"NCT01914770","phase":"","title":"Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-07","conditions":"Systemic Lupus Erythematosus","enrollment":1016},{"nctId":"NCT00556192","phase":"PHASE2","title":"Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2006-06","conditions":"Systemic Lupus Erythematosus","enrollment":20},{"nctId":"NCT00377637","phase":"PHASE3","title":"A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-07","conditions":"Lupus Nephritis","enrollment":370},{"nctId":"NCT00307671","phase":"PHASE4","title":"Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-07","conditions":"Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis","enrollment":108},{"nctId":"NCT01207297","phase":"PHASE1","title":"Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis","status":"COMPLETED","sponsor":"Zhejiang University","startDate":"2003-03","conditions":"SLE, Lupus Nephritis, Renal Insufficiency","enrollment":40},{"nctId":"NCT00615173","phase":"PHASE3","title":"Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2006-07","conditions":"Kidney Diseases, Lupus Nephritis, Tacrolimus","enrollment":81},{"nctId":"NCT00753103","phase":"PHASE2","title":"Anti-Cytokine Therapy for Vasculitis","status":"COMPLETED","sponsor":"University Hospital Birmingham NHS Foundation Trust","startDate":"2003-01","conditions":"Wegener's Granulomatosis, Renal Limited Vasculitis, Microscopic Polyangiitis","enrollment":37},{"nctId":"NCT00664599","phase":"PHASE2","title":"Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2006-04","conditions":"Behcet's Syndrome","enrollment":20},{"nctId":"NCT00349674","phase":"PHASE3","title":"WEGENT - Comparison of Methotrexate or Azathioprine as Maintenance Therapy for ANCA-Associated Vasculitides","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"1999-01","conditions":"Systemic Wegener's Granulomatosis","enrollment":126},{"nctId":"NCT00400075","phase":"PHASE4","title":"CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"1996-07","conditions":"Polyarteritis Nodosa, Microscopic Polyangiitis","enrollment":124},{"nctId":"NCT00399399","phase":"PHASE4","title":"CHUSPAN SCS BP Treatment of Churg-Strauss Syndrome Without Poor-Prognosis Factors","status":"UNKNOWN","sponsor":"Hospices Civils de Lyon","startDate":"1996-07","conditions":"Churg-Strauss Syndrome","enrollment":72},{"nctId":"NCT00307645","phase":"PHASE3","title":"IMPROVE: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2003-05","conditions":"ANCA Associated Systemic Vasculitis Including Wegener's, Granulomatosis and Microscopic Polyangiitis and, Renal Limited Vasculitis","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":201,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"cyclophosphamide/azathioprine","genericName":"cyclophosphamide/azathioprine","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclophosphamide is an alkylating agent that interferes with DNA replication, while azathioprine is a purine synthesis inhibitor that suppresses the immune system. Used for Treatment of certain types of cancer, such as lymphomas and leukemias, and autoimmune diseases, such as rheumatoid arthritis and lupus, Prevention of organ rejection in transplant patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}